Mitotane


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Inoperable adrenocortical tumours
Adult: Initially, 2-3 g daily in 2-3 divided doses; may be reduced to 1-2 g daily after 2 mth of treatment or until cumulative dose of 200 g or in the event of toxicity. If plasma monitoring is available, initial dose may be 4-6 g in divided doses to a cumulative dose of 75 g (over about 15 days). Other dose recommendation: Initially, 2-6 g daily in 3-4 divided doses; increase to 9-10 g daily unless adverse effects necessitate dose reduction. Max tolerated dose: 2-16 g daily.
Child: Initially, 1.5-3.5 g/m2 daily in 2-3 divided doses; reduce after 2-3 mth depending on plasma levels.

Oral
Cushing's syndrome
Adult: 1-12 g daily. Secondary to pituitary disorders: Initially, 3-6 g daily in 3-4 divided doses. Maintenance: 500 mg twice wkly to 2 g daily.
Hepatic Impairment
Dose reduction may be required.
Cách dùng
Should be taken with food.
Thận trọng
Adrenocortical insufficiency may develop; corticosteroid therapy is often required. Temporarily discontinue treatment and administer systemic corticosteroids in cases of trauma, infection or shock. Renal or hepatic impairment. Surgically remove all possible tumour tissue from large metastases prior to therapy. Perform regular behavioural and neurological assessments in patients receiving treatment for ≥2 yr. Monitor plasma levels (therapeutic window: 14-20 mcg/l). Monitor hepatic function. May affect ability to drive or operate machinery. Pregnancy and lactation.
Phản ứng phụ
CNS depression, somnolence, dizziness/vertigo, headache, confusion; skin rash; anorexia, nausea, vomiting, diarrhoea; weakness, muscle tremor; albuminuria, blurred vision, diplopia, flushing, haematuria, haemorrhagic cystitis, hypertension, hyperpyrexia, lens opacity, myalgia, orthostatic hypotension, decreased protein-bound iodine, toxic retinopathy.
Potentially Fatal: Possible permanent brain damage.
Quá liều
Symptoms: Diarrhoea, vomiting, numbness of limbs, weakness. Management: Symptomatic and supportive.
Tương tác
May reduce the effects of coumarin anticoagulants, barbiturates, phenytoin. Reduced effects with spironolactone. CNS depression may occur with alcohol.
Food Interaction
Absorption increases with food.
Lab Interference
Urinary tetrahydrocortisol and tetrahydrocortisone glucuronides (measurable 17-OHCS) may be reduced in the 1st several wk of mitotane therapy. May interfere with certain thyroid function tests since it competitively binds to thyroxine-binding globulin and decreases serum protein-bound iodine.
Tác dụng
Description: Mitotane is an antineoplastic with a selective inhibitory action on adrenal cortex activity causing tissue necrosis and atrophy. It can also modify peripheral metabolism of steroids.
Pharmacokinetics:
Absorption: 35-40% of a dose absorbed from the GI tract; absorption increases with food.
Distribution: Widely distributed and appears to be stored mainly in fatty tissues.
Metabolism: Metabolised in the liver and other tissues.
Excretion: Via urine and bile as metabolites. Elimination half-life: 18-159 days.
Bảo quản
Store at room temperature.
Phân loại MIMS
Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Mitotane từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in